Antibe Therapeutics is a clinical-stage biotechnological company developing novel drugs primarily focusing on reducing pain and inflammation
India's bio economy has experienced remarkable growth, skyrocketing from $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
New research labs and process development services to enable next generation therapeutics
Genext Genomics can now offer comprehensive solutions that support the growth of India’s biotech ecosystem
Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China
It is the first autotaxin inhibitor to be investigated in cancer patients
Subscribe To Our Newsletter & Stay Updated
